Stober T, Schimrigk K, Dietzsch S, Thielen T
J Neurol. 1985;232(1):13-4. doi: 10.1007/BF00314033.
Six patients with amyotrophic lateral sclerosis were given from 800 to 4000 micrograms of thyrotropin-releasing hormone (TRH) intrathecally for a period of 2-6 months. The progressive course of this disease, manifested by increasing atrophy, paralysis and disability score, was not altered. This supports the hypothesis that the decrease in TRH content in the anterior horn region is secondary to the cellular destruction. TRH appears to play no significant role in the pathogenesis of amyotrophic lateral sclerosis.
六名肌萎缩侧索硬化症患者接受了鞘内注射800至4000微克促甲状腺激素释放激素（TRH）的治疗，为期2至6个月。该疾病的进展过程，表现为萎缩加剧、瘫痪及残疾评分增加，并未改变。这支持了以下假说：前角区域TRH含量的降低是细胞破坏的继发结果。TRH似乎在肌萎缩侧索硬化症的发病机制中不起重要作用。
